The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk

By Swaroop Mathen, Senior Director, Chemical Development at Cambrex High Point

Phase-appropriate development helps drug developers balance scientific rigor, speed, and investment when uncertainty is high. But not every early decision is limited to the phase in which it is made.

Choices around synthesis, raw materials, manufacturing operations, analytical methods, and impurity control can create requirements that become increasingly difficult or costly to address as a program advances. The challenge is knowing where to prioritize immediate needs and where decisions require a longer-term perspective.

Bringing development and manufacturing expertise into the process at the right time can help teams identify potential limitations while there is still flexibility to address them. Download the full article to learn how to keep today’s development decisions aligned with tomorrow’s manufacturing priorities.